Rigel CFO exercises stock options and covers taxes

Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno exercised stock options and settled related taxes in shares.

Rhea-AI Filing Summary

Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno exercised stock options and settled related taxes in shares. On June 1, 2026, he exercised options for 2,181 shares of common stock at $12.70 per share and 1,200 shares at $18.70 per share. To cover tax obligations, 928 shares of common stock were disposed of at a value of $29.86 per share, a tax-withholding transaction rather than an open-market sale. Following these transactions, he directly held 78,790 shares of Rigel common stock. The filing also notes all share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.

Insider Trade Summary

3,381 shares exercised/converted

Exercise 5 txns

Insider Schorno Dean L

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	1,200	$0.00	$0.00
Exercise	Employee Stock Option (right to buy)	2,181	$0.00	$0.00
Exercise	Common Stock	1,200	$18.70	$22K
Exercise	Common Stock	2,181	$12.70	$28K
Exercise Price or Tax Liability	Common Stock	928	$29.86	$28K

Holdings After Transaction: Employee Stock Option (right to buy) — 23,150 contracts (Direct); Common Stock — 78,790 shares (Direct)

Footnotes (3)

1. F1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
2. F2. The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.
3. F3. The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period.

Key Figures

Options exercised at $12.70: 2,181 shares Options exercised at $18.70: 1,200 shares Shares used for tax withholding: 928 shares at $29.86 +5 more

8 metrics

Options exercised at $12.70 2,181 shares Employee stock options exercised on June 1, 2026 at $12.70

Options exercised at $18.70 1,200 shares Employee stock options exercised on June 1, 2026 at $18.70

Shares used for tax withholding 928 shares at $29.86 Tax-withholding disposition of common stock on June 1, 2026

Common shares held after transactions 78,790 shares Direct ownership following June 1, 2026 transactions

Remaining options (grant 1) 13,518 options Employee stock option, expiration January 23, 2034

Remaining options (grant 2) 9,632 options Employee stock option, expiration January 26, 2033

Reverse stock split ratio 1-for-10 Effective June 27, 2024; all share counts adjusted

Total options exercised 3,381 shares Exercise count in transaction summary for June 1, 2026

Key Terms

Employee Stock Option (right to buy), tax-withholding disposition, derivative security, one-for-ten reverse stock split, +1 more

5 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition" for 928 shares"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

one-for-ten reverse stock split financial

"footnote: "adjusted to reflect the one-for-ten reverse stock split""

vesting commencement date financial

"footnotes describe options vesting from the vesting commencement date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGEL PHARMACEUTICALS (RIGL) report for Dean L. Schorno?

Rigel reported that EVP & CFO Dean L. Schorno exercised employee stock options for 3,381 shares of common stock and used 928 shares to satisfy tax obligations, leaving him with 78,790 directly held shares after the transactions.

How many Rigel (RIGL) shares did the CFO acquire and at what prices?

Dean L. Schorno exercised options to acquire 2,181 Rigel common shares at a strike price of $12.70 and 1,200 shares at $18.70. These exercises convert previously granted options into directly owned common stock.

Did the Rigel (RIGL) CFO sell shares in the market in this Form 4?

The Form 4 shows a disposition of 928 shares valued at $29.86 each, classified as tax-withholding. This represents shares delivered to cover tax liabilities, not an open-market sale decision by the CFO.

How many RIGL shares does the Rigel CFO hold after these transactions?

After the reported option exercises and tax-withholding disposition, Dean L. Schorno directly holds 78,790 shares of Rigel common stock. This figure reflects all adjustments from the one-for-ten reverse stock split noted in the filing.

What does the reverse stock split note mean for Rigel (RIGL) share counts?

The filing states all numbers are adjusted for a one-for-ten reverse stock split effective June 27, 2024. This means each block of ten pre-split shares became one share, and all reported holdings and option amounts use the post-split basis.

How do the Rigel (RIGL) CFO’s remaining employee stock options vest?

The options vest in monthly installments. One grant vests over four years from January 1, 2023, and another over three years from January 23, 2024, subject to Dean L. Schorno’s continued service with Rigel Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 06:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schorno Dean L

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		M		1,200	A	$18.7	77,537	D
Common Stock	06/01/2026		M		2,181(1)	A	$12.7(1)	79,718	D
Common Stock	06/01/2026		F		928	D	$29.86	78,790	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$18.7	06/01/2026		M			1,200	(2)	01/26/2033	Common Stock	1,200	$0	9,632	D
Employee Stock Option (right to buy)	$12.7(1)	06/01/2026		M			2,181(1)	(3)	01/23/2034	Common Stock	2,181(1)	$0	13,518(1)	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

2. The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

3. The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period.

	/s/ Raymond Furey (Attorney-in-Fact)	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)